AdvanDx, Inc. Release: Study Reveals PNA FISH Significantly Reduces Mortality Associated With S. aureus Bloodstream Infections in the ICU

Woburn, MA, May 7, 2007– AdvanDx, Inc. announced a group of infectious disease specialists, headed by Shmuel Shoham M.D. at the Washington Hospital Center, revealed new clinical data that demonstrated how AdvanDx, Inc.’s PNA FISH diagnostic test significantly reduced mortality and hospital costs associated with staphylococcal bloodstream infections (BSI). PNA FISH is a rapid, molecular-based test that identifies bacteria and yeast species directly from positive blood cultures. Results are available within hours instead of days, enabling labs to quickly report results to physicians and pharmacists to ensure optimal therapy and reduced death rates for patients afflicted with staphylococcal bloodstream infections.